Metraipolis › archive › dc_1028b48cbeaa

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive… — Europe PMC PMID:41393154

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41393154
DOI
10.3389/fmed.2025.1687242
License (as archived)
solo-consultazione
Archived
2026-11-08T04:39:22.744Z
SHA-256 of the archived text
795782602d582bf9c5ca9559699676d803aeceee1a2bf0da48b022940a0e87c3
Stable URL of this page
https://metraipolis.com/documento/dc_1028b48cbeaa

How to cite

Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive… — Europe PMC PMID:41393154 — Europe PMC (en), https://europepmc.org/article/MED/41393154 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1028b48cbeaa (Metraipolis archive dc_1028b48cbeaa, sha256 795782602d582bf9c5ca9559699676d803aeceee1a2bf0da48b022940a0e87c3)
BibTeX
@misc{dc1028b48cbeaa,
  title = {Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive… — Europe PMC PMID:41393154},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41393154},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1028b48cbeaa; sha256 795782602d582bf9c5ca9559699676d803aeceee1a2bf0da48b022940a0e87c3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41393154. Agents can read the archived copy with the MCP tool read_document.